| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Cortexyme, Inc. | EVP, Preclinical Development | Common Stock | 148,080 | $139,195 | $0.9400 | 06 Jun 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| QNCX | Cortexyme, Inc. | 06 Jun 2022 | 1 | -$31,231 | 4 | EVP, Preclinical Development | 08 Jun 2022, 16:10 |
| QNCX | Cortexyme, Inc. | 03 Mar 2022 | 1 | $0 | 4 | EVP, Preclinical Development | 04 Mar 2022, 16:48 |
| QNCX | Cortexyme, Inc. | 03 Jan 2022 | 1 | $0 | 4 | EVP, R&D | 05 Jan 2022, 15:57 |